Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04670965 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
StoppedWithdrawn before enrollingSponsor's reason: The study was stopped due to the funding issues.Enrollment target: estimated 20 to confirmed 0 · Interventions: E-PRF only (Biological), E-PRF/ACS/rhBMP-2 (Biological), E-PRF/rhBMP-2 (similar ratios) (Biological), rhBMP-2/E-PRF (Biological) to E-PRF only (Biological), E-PRF/ACS/rhBMP-2 (Biological), E-PRF/rhBMP-2 (similar ratios) (Biological), rhBMP-2/E-PRF (Biological) · Eligibility criteria expanded, about 10 wordsShow 3 more changesShow less
Enrollment target: estimated 20 to confirmed 0
Interventions: E-PRF only (Biological), E-PRF/ACS/rhBMP-2 (Biological), E-PRF/rhBMP-2 (similar ratios) (Biological), rhBMP-2/E-PRF (Biological) to E-PRF only (Biological), E-PRF/ACS/rhBMP-2 (Biological), E-PRF/rhBMP-2 (similar ratios) (Biological), rhBMP-2/E-PRF (Biological)
Eligibility criteria expanded, about 10 words
NotableStart date: Apr 2026 to Sep 2026v16
NotablePrimary completion date: Dec 2026 to Dec 2027Start date: Dec 2025 to Apr 2026 · Completion date: Jul 2027 to Jul 2028v15Show 2 more changesShow less
Start date: Dec 2025 to Apr 2026
Completion date: Jul 2027 to Jul 2028
NotableStart date: Aug 2025 to Dec 2025Primary completion date: Aug 2026 to Dec 2026 · Completion date: Feb 2027 to Jul 2027v14Show 2 more changesShow less
Primary completion date: Aug 2026 to Dec 2026
Completion date: Feb 2027 to Jul 2027
NotableStart date: Feb 2025 to Aug 2025Primary completion date: Feb 2026 to Aug 2026v13Show 1 more changeShow less
Primary completion date: Feb 2026 to Aug 2026
Show 11 earlier versionsHide 11 earlier versions
NotableStart date: Dec 2024 to Feb 2025Primary completion date: Dec 2025 to Feb 2026 · Completion date: Dec 2026 to Feb 2027v12Show 2 more changesShow less
Primary completion date: Dec 2025 to Feb 2026
Completion date: Dec 2026 to Feb 2027
NotableStart date: Aug 2024 to Dec 2024v11
NotablePrimary completion date: Dec 2024 to Dec 2025Start date: Dec 2023 to Aug 2024 · Completion date: Dec 2025 to Dec 2026v10Show 2 more changesShow less
Start date: Dec 2023 to Aug 2024
Completion date: Dec 2025 to Dec 2026
MinorRe-verified, no change to tracked fieldsv9
NotablePrimary completion date: Dec 2023 to Dec 2024Start date: Aug 2022 to Dec 2023 · Completion date: Dec 2024 to Dec 2025v8Show 2 more changesShow less
Start date: Aug 2022 to Dec 2023
Completion date: Dec 2024 to Dec 2025
NotablePrimary completion date: Dec 2022 to Dec 2023Start date: Feb 2022 to Aug 2022 · Completion date: Jan 2023 to Dec 2024v7Show 2 more changesShow less
Start date: Feb 2022 to Aug 2022
Completion date: Jan 2023 to Dec 2024
NotablePrimary completion date: Dec 2021 to Dec 2022Start date: Dec 2021 to Feb 2022 · Completion date: Jan 2022 to Jan 2023v6Show 2 more changesShow less
Start date: Dec 2021 to Feb 2022
Completion date: Jan 2022 to Jan 2023
NotableStart date: Sep 2021 to Dec 2021v5
NotableStart date: Jun 2021 to Sep 2021v4
NotableStart date: Feb 2021 to Jun 2021v3
MinorStart date: Jan 2021 to Feb 2021Study description revisedv2Show 1 more changeShow less
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is seeking to evaluate the binding of a commercially-available, recombinant human osteoinductive growth factor, rhBMP-2, to a human blood derived product scaffold, enhanced Platelet-rich fibrin (E-PRF), and the release of such a growth factor over time in an in vitro (laboratory) environment. The investigators will compare these release kinetics to those of the FDA approved carrier for rhBMP-2, an absorbable collagen sponge (ACS), a combination of E-PRF and ACS, and E-PRF alone.